NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (RAPH), a clinical-stage biotechnology company developing an innovative research platform based on cannabinoids free of THC and ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company developing an innovative ...

Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications The provisional patent application describes novel nanoparticle ...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH) , a clinical-stage biotechnology company developing an innovative ...

Additional provisional patent application, strengthens IP portfolio of therapeutics for the treatment of mild traumatic brain injuries (mTBI) with PTSD or PTSD alone. "The goal at Eleusian has been to ...

“Refiling a provisional is just a bad idea when you can, for a few hundred dollars more, keep hold of that earliest priority date and continue on the path to obtaining a patent.” The question that we ...

Since the U.S. patent law switched to the first-inventor-to-file system in 2013, provisional applications have become more popular as the initial step for emerging companies to protect their ...

LegalZoom Launches Streamlined Provisional Patent Filing Product to Help Businesses and Entrepreneurs Protect Intellectual Property, Secure Funding and Drive Growth LegalZoom’s law firm to provide ...